10-21-02

2 4 2002

1642

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU110396487US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 18, 2002

signature: Hur

TECH CENTER 1600/2900

Docket No.: HO-P02188US0

(PATENT)

OCT 1 8 2002 (S)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Goran Forsberg, et al.

Application No.: 09/900,766

Group Art Unit: 1642

Filed: July 6, 2001

Examiner: Caputa, Anthony C.

For: NOVEL ENGINEERED SUPERANTIGEN FOR

HUMAN THERAPY

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed are the following items for filing in connection with the above-referenced Patent Application:

- 1. Response to Restriction Requirement
- 2. Return Post Card

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10104199 from which the undersigned is authorized to draw.

Dated: October 18, 2002

Respectfully-submitted,

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100 Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

I hereby certify that this contained is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU110396487US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231,

Dated: October 18, 2002

Signature:

Docket No.: HO-P02188US0 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 2 4 2002

n re Patent Application of: Goran Forsberg, et al.

Application No.: 09/900,766

Group Art Unit: 1642 TECH CENTER 1600/2900

Filed: July 6, 2001

Examiner: Caputa, Anthony C.

For: NOVEL ENGINEERED SUPERANTIGEN FOR

HUMAN THERAPY

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed September 20, 2002 (Paper No. 7), applicants hereby provisionally elect Group III, Claims 15-34 and Claims 53-72 for continued examination, without traverse. The elected claims are drawn to a conjugate comprising a bacterial superantigen with amino acid substitutions in region C and an antibody.

The Examiner has also required a species election if Group III was elected. In response to the species election, Applicants hereby provisionally elect the following species: staphylococcal enterotoxin (SE), SEQ. ID. NO. 2 and lung cancer for the prosecution on their merits.

Application No.: 09/y00,766

Docket No.: HO-P02188US0

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10104199 from which the undersigned is authorized to draw.

Dated: October 18, 2002

Respectfully submitted,

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100 Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)